GLOBOCAN 2012 database, NIH Cancer fact sheet 2010
 
About Biocon

Established in 1978, Biocon Limited, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patients worldwide. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN®, Glargine, BASALOG® and India's first biologic BioMAb-EGFR ™ for head & neck cancer. It has also successfully developed its second novel biologic Itolizumab, a ‘first in class’ anti-CD6 monoclonal antibody, introduced as Alzumab™ for psoriasis in India, in 2013. Visit: www.biocon.com

  Media Contact Details

Seema Ahuja, Head-Corporate Communications Biocon, ,+919972317792 , [email protected]

Rumman Ahmed, Manager-Corporate Communications Biocon, ,+919845104173 , [email protected]

Dr. Nagaraj B Malipatil, Medical Advisor, Biocon Onco-therapeutics Biocon, ,+918067751107 , [email protected]

Saurabh Paliwal, Head-Investor Relations Biocon, ,+919538380801 , [email protected]

Sweta Pachlangiya, Deputy Manager-Investor Relations Biocon, ,+919686509372 , [email protected]